Literature DB >> 10807257

Pituitary carcinoma containing gonadotropins: treatment by radical excision and cytotoxic chemotherapy: case report.

I E McCutcheon1, D R Pieper, G N Fuller, R S Benjamin, K E Friend, R F Gagel.   

Abstract

OBJECTIVE AND IMPORTANCE: Pituitary carcinomas are extremely rare. Cases reported in the medical literature in the 20th century included tumors that produced adrenocorticotropic hormone, prolactin, growth hormone, and/or thyrotropin. CLINICAL
PRESENTATION: Here we present a 22-year-old woman with a pituitary carcinoma that was immunohistochemically positive for luteinizing hormone and follicle-stimulating hormone at both the primary and metastatic sites. The patient exhibited elevated serum levels of alpha-subunit. INTERVENTION: The patient had experienced failure of previous treatments, including standard surgery and radiotherapy, and presented to us for radical resection of the tumor, with exenteration of the involved cavernous sinus. She was pretreated with cytotoxic chemotherapy and continued to receive this therapy after surgery.
CONCLUSION: This is the only documented case of a gonadotropin-staining pituitary carcinoma for which hormone production was proven in both the primary and metastatic tumors. Many benign "nonsecreting" pituitary adenomas actually produce subclinical amounts of gonadotropins, and malignant nonfunctional pituitary neoplasms may do the same.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807257     DOI: 10.1097/00006123-200005000-00042

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  18 in total

Review 1.  Clinical review: Pituitary carcinoma: difficult diagnosis and treatment.

Authors:  Anthony P Heaney
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

Review 2.  Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review.

Authors:  Frederick Yoo; Edward C Kuan; Anthony P Heaney; Marvin Bergsneider; Marilene B Wang
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

3.  Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.

Authors:  Carlos Kamiya-Matsuoka; David Cachia; Steven G Waguespack; Christopher H Crane; Anita Mahajan; Paul D Brown; Joo Yeon Nam; Ian E McCutcheon; Marta Penas-Prado
Journal:  Pituitary       Date:  2016-08       Impact factor: 4.107

Review 4.  Pituitary carcinoma: report of an exceptional case and review of the literature.

Authors:  C Pichard; S Gerber; M Laloi; M Kujas; S Clemenceau; D Ponvert; E Bruckert; G Turpin
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

5.  Non-functioning pituitary carcinoma.

Authors:  Petra Nadja Elsässer Imboden; François-Xavier Borruat; Nicolas De Tribolet; Kathleen Meagher-Villemure; Alesia Pica; Fulgencio Gomez
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 6.  Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).

Authors:  Nèle Lenders; Ann McCormack
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 7.  Corticotroph pituitary carcinoma: case report and literature review.

Authors:  D J Holthouse; P D Robbins; R Kahler; N Knuckey; P Pullan
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

8.  Pathological changes after radiotherapy for primary pituitary carcinoma: a case report.

Authors:  Hideomi Yamashita; Keiichi Nakagawa; Masao Tago; Naoki Nakamura; Kenshiro Shiraishi; Naoko Yamauchi; Kuni Ohtomo
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

Review 9.  Management of aggressive pituitary adenomas and pituitary carcinomas.

Authors:  Anthony Heaney
Journal:  J Neurooncol       Date:  2014-03-02       Impact factor: 4.130

10.  Malignant prolactinoma with craniospinal metastasis in a 12-year-old boy.

Authors:  Abel Po-Hao Huang; Shih-Hung Yang; Chi-Cheng Yang; Meng-Fai Kuo; Mu Zon Wu; Yong-Kwang Tu
Journal:  J Neurooncol       Date:  2008-07-12       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.